Novel Drug Delivery Systems in Cancer Therapy Market Introduction and Overview
According to SPER Market Research, the Global Novel Drug Delivery Systems in Cancer Therapy Market is estimated to reach USD 38.09 billion by 2034 with a CAGR of 7.73%.
The report includes an in-depth analysis of the Global Novel Drug Delivery Systems in Cancer Therapy Market, including market size and trends, product mix, Applications, and supplier analysis. The global novel drug delivery systems in cancer therapy market was estimated at USD 18.09 billion in 2024 and is expected to increase at a CAGR of 7.73% between 2025 and 2034. The introduction of targeted medicines, precision medicine, and tailored treatment techniques, as well as the expanding use of less invasive procedures, are driving global market expansion. Furthermore, demand for innovative medication development is driven by the desire for effective therapeutic choices that improve patient outcomes while minimizing the negative effects associated with conventional therapies.
By Product Insights: Nanoparticles accounted for the biggest market revenue share in 2024, owing to their ability to improve therapeutic efficacy while reducing side effects. Nanoparticles enable tailored distribution, increasing drug stability and bioavailability while decreasing toxicity to healthy tissues. Advances in nanotechnology and increased investment in R&D boost this segment, making it a critical component in the evolution of cancer therapy.
By Regional Insights: North America dominated the global novel drug delivery systems in cancer therapy market in 2024. Growth in the region is driven by many manufacturers and funding for new treatment research. Several regulatory approvals are pending for novel medications using innovative drug delivery systems, which is expected to boost market expansion and strengthen North America’s healthcare position.
Market Competitive Landscape:
Some key companies in the novel drug delivery systems for cancer therapy are Bristol-Myers Squibb Company (Celgene Corporation), Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc., Galen Limited, and others. These manufacturers are focusing on expanding their customer base to gain a competitive edge in the market. As a result, major stakeholders are merging with other companies and forming partnerships with large corporations. Teva Pharmaceutical Industries Ltd develops medications for various health conditions, including cancer, and offers a range of generic products. Merrimack Pharmaceuticals specializes in targeted cancer therapies and aims to deliver innovative treatments in the U. S.
Recent Developments:
- Bristol-Myers Squibb Company got FDA accelerated approval in June 2024 for KRAZATI (adagrasib) in combination with cetuximab, a targeted treatment for KRASG12C-mutated CRC patients who had previously taken chemotherapy, based on ORR and DOR results.
- Johnson & Johnson purchased Ambrx Biopharma, a clinical-stage biopharmaceutical company, in a cash merger worth roughly USD 2.0 billion, after deducting projected cash on hand.
- Teva Pharmaceutical Industries Ltd. and Alvotech jointly launched SIMLANDI Injection in the United States in May 2024. This product launch strengthened the firm's standing in the country.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Bristol-Myers Squibb Company (Celgene Corporation), Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, Galen Limited, Shire (Takeda Pharmaceutical Company Limited), Samyang Holdings Corporation, Merrimack Pharmaceuticals, Spectrum Pharmaceuticals, Inc. |
Key Topics Covered in the Report:
- Global Novel Drug Delivery Systems in Cancer Therapy Market Size (FY’2021-FY’2034)
- Overview of Global Novel Drug Delivery Systems in Cancer Therapy Market
- Segmentation of Global Novel Drug Delivery Systems in Cancer Therapy Market By Product (Nanoparticles and Embolization Particles)
- Statistical Snap of Global Novel Drug Delivery Systems in Cancer Therapy Market
- Expansion Analysis of Global Novel Drug Delivery Systems in Cancer Therapy Market
- Problems and Obstacles in Global Novel Drug Delivery Systems in Cancer Therapy Market
- Competitive Landscape in the Global Novel Drug Delivery Systems in Cancer Therapy Market
- Details on Current Investment in Global Novel Drug Delivery Systems in Cancer Therapy Market
- Competitive Analysis of Global Novel Drug Delivery Systems in Cancer Therapy Market
- Prominent Players in the Global Novel Drug Delivery Systems in Cancer Therapy Market
- SWOT Analysis of Global Novel Drug Delivery Systems in Cancer Therapy Market
- Globa Novel Drug Delivery Systems in Cancer Therapy Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Novel Drug Delivery Systems in Cancer Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Novel Drug Delivery Systems in Cancer Therapy Market
7. Global Novel Drug Delivery Systems in Cancer Therapy Market, By Product (USD Million) 2021-2034
7.1. Nanoparticles
7.1.1. Liposomes
7.1.2. Polymers
7.1.3. Micelles
7.1.4. Other Nanoparticles
7.2. Embolization Particles
7.2.1. PVA Particles
7.2.2. Drug Eluting Beads
7.2.3. Liquid Emboli
7.2.4. Other Embolization Particles
8. Global Novel Drug Delivery Systems in Cancer Therapy Market, (USD Million) 2021-2034
8.1. Global Novel Drug Delivery Systems in Cancer Therapy Market Size and Market Share
9. Global Novel Drug Delivery Systems in Cancer Therapy Market, By Region, (USD Million) 2021-2034
9.1. Asia-Pacific
9.1.1. Australia
9.1.2. China
9.1.3. India
9.1.4. Japan
9.1.5. South Korea
9.1.6. Rest of Asia-Pacific
9.2. Europe
9.2.1. France
9.2.2. Germany
9.2.3. Italy
9.2.4. Spain
9.2.5. United Kingdom
9.2.6. Rest of Europe
9.3. Middle East and Africa
9.3.1. Kingdom of Saudi Arabia
9.3.2. United Arab Emirates
9.3.3. Qatar
9.3.4. South Africa
9.3.5. Egypt
9.3.6. Morocco
9.3.7. Nigeria
9.3.8. Rest of Middle-East and Africa
9.4. North America
9.4.1. Canada
9.4.2. Mexico
9.4.3. United States
9.5. Latin America
9.5.1. Argentina
9.5.2. Brazil
9.5.3. Rest of Latin America
10. Company Profile
10.1. Bristol-Myers Squibb Company (Celgene Corporation)
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Teva Pharmaceutical Industries Ltd
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Johnson & Johnson Services, Inc
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Galen Limited
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Shire (Takeda Pharmaceutical Company Limited)
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Samyang Holdings Corporation
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Merrimack Pharmaceuticals
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Spectrum Pharmaceuticals, Inc
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Others
11. Conclusion
12. List of Abbreviations
13. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
